Fresenius Loses IP Over Liquid 'Humira' Biosimilar
Fresenius has lost a patent over a biosimilar version of a blockbuster arthritis drug, after European officials ruled that scientists at the time would have arrived at its claimed formula by...To view the full article, register now.
Already a subscriber? Click here to view full article